Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

February 20, 2024 updated by: LB Pharmaceuticals Inc.

A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Acute Schizophrenia

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to examine the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. The primary objective of the study is to assess the efficacy of LB-102 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores at day 28 in approximately 350 adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in CGI-S, PANSS subscale and Marder Factor scores, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia. The duration of treatment of the study is 28 days (4 weeks). Patients in this study will be randomized 3:3:3:1 to receive either: placebo, 50 mg QD LB-102, 75 mg QD LB-102, or 100 mg QD LB-102; that is, ~105 patients will get placebo, ~105 will get 50 mg LB-102 QD, ~105 will get 75 mg LB-102 QD, ~35 will get 100 mg LB-102 QD. LB-102 will be dosed orally once a day. Pharmacokinetic data will be measured for the first 60 patients in this study.

Study Type

Interventional

Enrollment (Estimated)

350

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Arkansas
      • Bentonville, Arkansas, United States, 72712
        • Recruiting
        • Pillar Clinical Research
        • Contact:
        • Principal Investigator:
          • Fayz Hudefi, MD
        • Contact:
      • Little Rock, Arkansas, United States, 72211
        • Recruiting
        • Woodland Internation Research Group
        • Principal Investigator:
          • George Konis, MD
        • Contact:
        • Contact:
      • Rogers, Arkansas, United States, 72758
        • Recruiting
        • Woodland Research Northwest
        • Contact:
        • Principal Investigator:
          • Robert Billingsley, MD
    • California
      • Bellflower, California, United States, 90706
        • Recruiting
        • CelExel Clinical Innovations
        • Contact:
        • Principal Investigator:
          • Robert Bota, MD
        • Contact:
      • Cerritos, California, United States, 90703
      • Culver City, California, United States, 90230
      • Garden Grove, California, United States, 92845
      • Lemon Grove, California, United States, 91945
      • Riverside, California, United States, 92506
        • Recruiting
        • CenExel CIT Riverside
        • Contact:
        • Contact:
        • Principal Investigator:
          • Evagelos Coskinas, MD
      • Santa Ana, California, United States, 92705
    • Florida
      • Hollywood, Florida, United States, 33021
        • Recruiting
        • Behavioral Clinical Research, Inc.
        • Principal Investigator:
          • Olga Lapeyra, MD
        • Contact:
        • Contact:
      • Hollywood, Florida, United States, 33024
        • Recruiting
        • CenExel RCA
        • Contact:
        • Contact:
        • Principal Investigator:
          • Edwin Gomez, MD
      • Miami Lakes, Florida, United States, 33016
        • Recruiting
        • Segal Institute for Clinical Research
        • Principal Investigator:
          • Rishi Kakar, MD
        • Contact:
        • Contact:
    • Georgia
      • Atlanta, Georgia, United States, 30331
        • Recruiting
        • CenExel ACMR
        • Principal Investigator:
          • Maria Johnson, MD
        • Contact:
      • Decatur, Georgia, United States, 30030
        • Recruiting
        • CenExel iResearch
        • Contact:
        • Contact:
        • Principal Investigator:
          • Saundra Maas-Robinson, MD
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Recruiting
        • Uptown Research Institute
        • Contact:
        • Contact:
        • Principal Investigator:
          • John G Sonnenberg, PhD
        • Sub-Investigator:
          • Alecia E Halstead
      • Chicago, Illinois, United States, 60641
        • Recruiting
        • Pillar Clinical Research
        • Principal Investigator:
          • Roueen Rafeyan, MD
        • Contact:
        • Contact:
    • Maryland
      • Gaithersburg, Maryland, United States, 20877
        • Recruiting
        • CenExel CBH
        • Principal Investigator:
          • Elia Acevedo-Diaz, MD
        • Contact:
        • Contact:
    • New Jersey
      • Berlin, New Jersey, United States, 08009
        • Recruiting
        • CenExel HRI
        • Principal Investigator:
          • Elan Cohen, PhD
        • Contact:
        • Contact:
    • New York
      • Staten Island, New York, United States, 10314
        • Recruiting
        • Richmond Behavioral Associates
        • Contact:
        • Contact:
        • Principal Investigator:
          • Adam Smith, PhD
    • Ohio
      • Dayton, Ohio, United States, 45417
        • Recruiting
        • Midwest Clinical Research Center
        • Contact:
        • Contact:
        • Principal Investigator:
          • Richard Sanders, MD
      • North Canton, Ohio, United States, 44720
        • Recruiting
        • Neuro-Behavioral Clinical Research
        • Principal Investigator:
          • Shishuka Malhotra, MD
        • Contact:
        • Contact:
    • Texas
      • Austin, Texas, United States, 78754
      • DeSoto, Texas, United States, 75115
        • Recruiting
        • InSite Clinical Research
        • Principal Investigator:
          • Rajinder Shiwach, MD
        • Contact:
        • Contact:
      • Richardson, Texas, United States, 75080
        • Recruiting
        • Pillar Clinical Research
        • Principal Investigator:
          • Scott Bartley, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

A patient will be eligible for inclusion in the study if they meet all of the following criteria:

  1. Patient who is able to provide written informed consent (as required by Institutional Review Board [IRB]) prior to the initiation of any protocol-required procedures.
  2. Must be willing to be hospitalized for the duration of the inpatient period of the study.
  3. Have stable living environment when not in a hospital.
  4. Male and female patients 18 to 55 years of age inclusive at the time of informed consent with a diagnosis of schizophrenia as defined by DSM-5 criteria and confirmed by the MINI 7.0.2 .
  5. Body mass index (BMI) must be ≥18 and ≤40 kg/m2.
  6. Patient who experiencing an acute exacerbation of psychotic symptoms, AND the patient requires hospitalization OR if already an inpatient at Screening, has been hospitalized for onset < 2 weeks for the current exacerbation.

  7. Patients who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the Screening and Baseline visits:

    • Total PANSS score between 80 and 120, inclusive, and
    • Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items: Item 1 (P1; delusions), Item 2 (P2; conceptual disorganization), Item 3 (P3; hallucinatory behavior), Item 6 (P6; suspiciousness/persecution), and
    • CGI-S score ≥4 (moderately to severely ill).
  8. Have received previous antipsychotic treatment (dose and duration as per the label) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the Investigator's opinion.
  9. Have history of relapse and/or exacerbation of symptoms when they were not receiving antipsychotic treatment.
  10. Patients willing to discontinue all prohibited psychotropic medications prior to Screening, if determined to be clinically appropriate by the Investigator, and not for the sole purpose of inclusion in the trial.

Exclusion Criteria:

A patient will be excluded from the study if they meet any of the following criteria:

Sex and Reproductive Status

  1. Sexually active females of childbearing potential and male patients who are not practicing 2 different methods of birth control with their partner during the trial and for 30 days after the last dose of trial medication or who would not remain abstinent during the trial and for 30 days after the last dose.
  2. Females who are breastfeeding or who have a positive pregnancy test result prior to receiving trial medication.
  3. Patients who presented with a first episode of schizophrenia.
  4. Improvement of ≥20% in total PANSS score between the Screening and Baseline assessments.
  5. History of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (dose and duration as per the label) or required clozapine within the last 12 months.
  6. Current DSM-5 Axis I diagnosis other than schizophrenia.
  7. Risk for suicidal behavior during the study.
  8. Risk of violent or destructive behavior.
  9. Patients with clinically significant tardive dyskinesia.
  10. Patients with a score of 3 on the Barnes Akathisia Rating Scale (BARS) global clinical assessment of akathisia.
  11. Patients who met DSM-5 criteria for substance abuse or dependence within the past 1 year.
  12. Patients with hypothyroidism or hyperthyroidism or clinically significant abnormal thyroid function.
  13. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.

  14. Patients with insulin-dependent diabetes mellitus (i.e., any patient using insulin) are excluded. Patients with non-insulin-dependent diabetes mellitus may be eligible for the trial if their condition is stable as determined by satisfying ALL of the following criteria:

    • Glycosylated hemoglobin (HbA1c) <7.0%, and
    • Screening glucose must have been ≤125 mg/dL or ≤6.94 mmol/L (fasting) or <200 mg/dL or <11.1 mmol/L (nonfasting), and
    • Patient had been maintained on a stable regimen of oral antidiabetic medication(s) for at least 28 days prior to Screening or diabetes had been well controlled by diet for at least 28 days prior to Screening, and
    • Patient had no hospitalizations within the 12 months prior to Screening due to diabetes or complications related to diabetes, and
    • Patient's diabetes should not be newly diagnosed during Screening for the trial.
  15. Patients with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
  16. Patients with known ischemic heart disease or any history of myocardial infarction, congestive heart failure.
  17. Patients with epilepsy or a history of seizures.
  18. Patients with a positive urine drug screen or a positive blood alcohol test.
  19. Patients with a history of alcohol use or substance use disorder (by DSM-5 criteria) within 12 months of Screening or a positive screen for drugs of abuse at Screening.

  20. The following laboratory test results are exclusionary:

    • Platelets ≤75,000/µL or ≤75×109/L
    • Hemoglobin ≤9 g/dL or ≤90 g/L
    • Neutrophils, absolute ≤1000/µL or ≤1×109/L
    • AST and ALT >2 × upper limit of normal (ULN)
    • CPK >3 × ULN, unless discussed with and approved by the Medical Monitor
    • Creatinine ≥2 mg/dL or ≥176.8 µmol/L
    • Estimated creatinine clearance of <45 mL/min, calculated using the Cockcroft-Gault equation, at Screening
    • HbA1c ≥7.0%
    • Abnormal free T4 (during Screening), unless discussed with and approved by the Medical Monitor.
  21. Clinically significant abnormal finding on the triplicate set of electrocardiograms (ECGs) or evidence of any of the following cardiac conduction abnormalities at Screening.
  22. Patients who are currently taking oral antipsychotic medications, monoamine oxidase inhibitors (MAOIs), anticonvulsants (e.g., lamotrigine, Depakote), tricyclic antidepressants (e.g., imipramine, desipramine), selective serotonin reuptake inhibitors, and any other antidepressants or any other psychoactive medications (except lorazepam, zolpidem, zaleplon, eszopiclone, or similar benzodiazepines, diphenhydramine, benztropine, and propranolol). The medications should not be discontinued solely to make the patient eligible for enrollment in the study.
  23. Patients who received electroconvulsive therapy, or Transcranial Magnetic Stimulation (TMS).
  24. Patients with a history of neuroleptic malignant syndrome.
  25. Patients with a history of allergic response
  26. Prisoners or patients who were compulsorily detained (involuntarily hospitalized) for treatment of either a psychiatric or physical illness or have been in the last 6 months prior to the Screening Visit

  27. Patients who have participated in another clinical study in which they received an experimental or investigational drug agent within 3 months of Screening.

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: LB-102, 50 mg QD
Oral LB-102: 50 mg (n ~ 105)
Drug: LB-102
LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Experimental: LB-102, 75 mg QD
Oral LB-102: 75 mg (n ~ 105)
Drug: LB-102
LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Experimental: LB-102, 100 mg
Oral LB-102: 100 mg (n ~ 35)
Drug: LB-102
LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Placebo Comparator: Placebo comparator

Drug: Placebo

Matched placebo tablets
Drug: LB-102
LB-102 is a dopamine D2/3 and 5HT7 antagonist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 28 days
Time Frame: 28 days (4 weeks)
The PANSS is a scale used for measuring symptom severity of patients with schizophrenia. The PANSS rating is composed of 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Patients are scored from 1 to 7 on each symptom scale. The total score of the PANSS is a minimum of 30 and a maximum of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
28 days (4 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in the Clinical Global Impressions Severity of Illness scale (CGI-S) score
Time Frame: 28 days
The CGI-Severity rates illness severity on a scale from 1 to 7, and has been shown to correlate with PANSS.
28 days
Change from baseline on PANSS subscale and Marder factor scores
Time Frame: 28 days
The PANSS subscales (positive, negative, and general psychopathology) and Marder factors measure changes in total PANSS score by subtype.
28 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline on Cogstate test score
Time Frame: 28 days
Cogstate scores are a measure of cognition
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

LB Pharmaceuticals Inc.

Investigators

  • Principal Investigator: John Kane, MD, The Zucker Hillside Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 4, 2023

Primary Completion (Estimated)

September 30, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

December 12, 2023

First Submitted That Met QC Criteria

December 12, 2023

First Posted (Actual)

December 21, 2023

Study Record Updates

Last Update Posted (Estimated)

February 21, 2024

Last Update Submitted That Met QC Criteria

February 20, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LB-102-003

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on LB-102

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe